In all fairness she is speaking about vaccines in general. But DCVax-L does have more antigens. And this Phase III allows more more injections than the prior Phase studies. In every study they have run in GBM there remains survival.
Duke vaccine with one antigen CMV and a Tetanus shot, and hundreds of injections later, one survivor, a couple of long tail. They did feel that even without the tetanus "for migration" that one antigen did make a little difference. I believe the tetanus worked on immune memory and called T cells which then helped to put in Vivo immune cells on alert. But, it unless patients has high level CMV there was not an antigen to cause TIL within the tumor bed. In my view, DCVax-L will beat out long tail survival than Duke's promising approach.
He impressed that the first Phase I results did see an effect (even though at the vaccines had a mixed response). He said the Phase I was not powered to detect significance. Again, the Phase I is patients who had 1 (patient #9) or 3 DCVax-L injections, and the results were before standard of care approval of concurrent chemoradiation, which was proven to extend survival. None of the Phase I patients were treated under STUPP protocol.
Jenifer Sugioka is the first long-tail survivor. Again, no STUPP protocol and certainly not a patient that should be described as cherry picked. Her cancer infiltrated her brain, not any easy surgery when one thinks of the time period.
Market Data 
Markets 
AI
